Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2009-11-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study evaluate also local disease control after 18 months in patients with an ENT epidermoid carcinoma and treated by tomotherapy orarctherapy .
The number of patients required in this study is: 300:
* Number of patients treated with tomotherapy: 120
* Number of patients treated with dynamic arctherapy RapidArc: 120
* Number of patients treated with dynamic arctherapy Vmat: 60
This is a prospective; multicentric and non randomized study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tomotherapy
Radiotherapy
Arc'therapy Vmat
Radiotherapy
Arctherapy Rapid'Arc
Radiotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 18 years
* Histologically proven carcinoma
* Cavum Epidermoïd or undifferentiated carcinoma; or oropharynx epidermoïd carcinoma; or oral cavity epidermoïd carcinoma
* Stade T1 to T4
* M0
* Patient with no surgery ( except laser partial surgery and ganglionic cleaning out)
* Bilateral ganlionic cervical area irradiation
* Covered by a medical insurance.
Exclusion Criteria
* Re-irradiation indication
* Unilateral cervical area irradiation
* Post-operative radiotherapy
* Patient treated by amifostine
* Impossible follow-up
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Biostatistics and Therapy Evaluation Unit
OTHER
Centre Leon Berard
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe GIRAUD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hopital Europeen Georges Pompidou, Paris; FRANCE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Sainte Catherine
Avignon, , France
Institut BERGONIE
Bordeaux, , France
Centre Oscar Lambret
Lille, , France
Centre Léon Bérard
Lyon, , France
Centre Privé de Radiothérapie de Metz
Metz, , France
Centre Val d'Aurelle
Montpellier, , France
Centre Alexis Vautrin
Nancy, , France
Intitut Curie
Paris, , France
Hôpital Eurppéen Geoges POMPIDOU
Paris, , France
Centre Eugène Marquis
Rennes, , France
Centre René GAUDUCHEAU
Saint-Herblain, , France
Centre Paul STRAUSS
Strasbourg, , France
Groupe Oncorad Garonne
Toulouse, , France
Institut Claudius Regaud
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bibault JE, Dussart S, Pommier P, Morelle M, Huguet M, Boisselier P, Coche-Dequeant B, Alfonsi M, Bardet E, Rives M, Calugaru V, Chajon E, Noel G, Mecellem H, Servagi Vernat S, Perrier L, Giraud P. Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):929-937. doi: 10.1016/j.ijrobp.2017.06.2456. Epub 2017 Jun 27.
Bibault JE, Morelle M, Perrier L, Pommier P, Boisselier P, Coche-Dequeant B, Gallocher O, Alfonsi M, Bardet E, Rives M, Calugaru V, Chajon E, Noel G, Mecellem H, Perol D, Dussart S, Giraud P. Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer. Cancer Radiother. 2016 Jul;20(5):357-61. doi: 10.1016/j.canrad.2016.05.009. Epub 2016 Jun 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ET 2009-044
Identifier Type: -
Identifier Source: secondary_id
ART-ORL
Identifier Type: -
Identifier Source: org_study_id